ReviewACS infectious diseases2026
Biosensor-Based Platforms for the Detection and Screening of
Review in ACS infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leprosy remains an important neglected tropical disease with about 200,000 new cases detected annually worldwide. Although the disease is highly responsive to treatment, a timely and accurate diagnosis continues to be a critical barrier to disease control. Traditional diagnostic methods, including PCR, bacilloscopy, histopathology, and serology, are hindered by limited sensitivity, procedural complexity, and restricted accessibility in resource-constrained settings. This review summarizes studies from the past decade on biosensor-based strategies for leprosy diagnosis. Biosensor platforms for leprosy include electrochemical, piezoelectric, and optical systems, with recent innovations encompassing immunosensors, biomimetic, and DNA-based approaches, some achieving diagnostic accuracies above 90%. These platforms employ different bioreceptors such as conjugated peptides, DNA probes, and molecularly imprinted polymers. Certain platforms can also differentiate paucibacillary from multibacillary cases, addressing a critical limitation of the current methods. These capabilities highlight the potential of biosensors as powerful tools for point-of-care testing. However, clinical translation is constrained by challenges such as affordability, robustness under field conditions, and the lack of large-scale validation studies. Additional operational barriers, including regulatory approval, supply chain logistics, and user training, must also be addressed. Future progress will depend on multidisciplinary strategies, integrating novel biomarker discovery as recognition elements and exploring detection systems previously used for other mycobacterial and infectious diseases. Large multicenter trials and user-centered design approaches are essential for clinical implementation. By overcoming these challenges, biosensors have the potential to redefine leprosy diagnostics, enabling earlier detection and improved surveillance, and accelerating progress toward global elimination goals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.